Il-Yang Pharm. Co. registers Phase 3 trial of UROCOM-R1 plus UROCOM-R2
The study plans to enroll 660 participants and is expected to start on November 9, 2026. It plans to compare the efficacy and safety of UROCOM-R1 plus UROCOM-R2 combination therapy with UROCOM-R1 or UROCOM-R2 monotherapy in patients with benign prostatic hyperplasia.
Primary source
ClinicalTrials.gov registry record, October 13, 2026
Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia
Read the source: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation